Medtronic, Inc. (MDT:NYSE)

Medtronic Inc. announced the Conformite Europeen (CE) mark and international launch of the PoleStar(R) N30 Surgical MRI system, the latest in neuro oncology surgical solutions. The PoleStar N30 System has been submitted to the U.S. Food and Drug Administration for approval. Providing real-time imaging in the operating room (OR), the PoleStar Surgical MRI provides surgeons with targeting and navigational accuracy despite the anatomy movement that may occur during a procedure. With intra-operative imaging information, neurosurgeons have more confidence to achieve maximum tumor resection, while avoiding critical areas of the brain. Use of the PoleStar system may also reduce the need for revision surgeries and the length of stay at the hospital for the patient.

Medtronic Inc. announced study results from an oral presentation at the International Diabetes Federation's World Diabetes Congress held in Montreal, Canada. This scientific convention highlights the latest developments in clinical research aimed at improving diabetes management and outcomes. Improved Glycemic Control and Evidence for Beta Cell Preservation. In an oral presentation entitled, 'The ONSET trial of sensor-enhanced CSII in children with new onset type 1 diabetes,' results of a prospective, randomized, multi-center trial were shared. The physician-initiated study, performed in five pediatric centers, assessed whether children (ages 1-16) newly diagnosed with type 1 diabetes could achieve improved glycemic control using an insulin pump augmented with Personal continuous glucose monitoring (CGM), known as the MiniMed Paradigm(R) REAL-Time System, compared to a control group using a conventional insulin pump with self monitoring of blood glucose (SMBG).

Medtronic Inc. announced the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system. The study, called ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors), is being performed under an investigational device exemption (IDE) issued by the U.S. Food and Drug Administration and is expected to enroll a total of 50 subjects at up to ten medical centers in the United States over the next year. Medtronic is collaborating with urologists and interventionalists at each of the participating sites to design and execute the study in subjects who have had suboptimal response to PDE5 inhibitors, which include Viagra(R), Cialis(R) and Levitra(R). The study will evaluate the safety and improved erectile function of pelvic artery stenting, with results expected in 2011.